source
- Alkermes CEO targets orexin market after strong narcolepsy pill dataAlkermes' incoming chief executive outlined a strategy to compete with larger rivals in the emerging orexin drug class. Recent mid-June trial results showed the experimental oral compound alixorex…
- Precision strategies help de-risk rare disease therapy launchesCommercializing a rare disease therapy presents a high‑risk, high‑reward scenario for biotech firms. Small patient populations, stringent regulatory requirements, and the need to sustain value beyo…